Kura Oncology Announces Commencement of Public Offering of Common Stock
June 18 2019 - 03:01PM
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage
biopharmaceutical company focused on the development of precision
medicines for oncology, today announced that it has commenced an
underwritten public offering, subject to market and other
conditions, to issue and sell shares of its common stock. In
connection with the offering, Kura expects to grant the
underwriters a 30-day option to purchase up to an additional 15% of
the shares of its common stock offered in the public
offering. There can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the
offering.
SVB Leerink and Cowen are acting as joint
book-running managers in the offering.
The securities described above are being offered
by Kura pursuant to a shelf registration statement on Form S-3,
including a base prospectus, that was previously filed by Kura with
the Securities and Exchange Commission (the “SEC”) and that was
declared effective on November 21, 2018. A preliminary
prospectus supplement and accompanying prospectus relating to the
offering will be filed with the SEC and will be available for free
on the SEC’s website located at http://www.sec.gov. Copies of
the preliminary prospectus supplement and the accompanying
prospectus relating to the offering, when available, may be
obtained from SVB Leerink LLC, Attention: Syndicate Department, One
Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800)
808-7525, ext. 6132, or by email at syndicate@svbleerink.com, or
Cowen and Company, LLC c/o Broadridge Financial Services, 1155 Long
Island Avenue, Edgewood, NY 11717, Attention: Prospectus
Department, or by telephone at (631) 592-5973, or by email at
PostSaleManualRequests@broadridge.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy these securities,
nor shall there be any sale of these securities in any state or
other jurisdiction in which such offer, solicitation or sale would
be unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction.
About Kura Oncology
Kura Oncology is a clinical-stage
biopharmaceutical company committed to realizing the promise of
precision medicines for the treatment of cancer. Kura’s pipeline
consists of small molecule drug candidates that target cancer
signaling pathways where there is a strong scientific and clinical
rationale to improve outcomes by identifying those patients most
likely to benefit from treatment. Kura’s lead drug candidate is
tipifarnib, a farnesyl transferase inhibitor, for which Kura has
initiated a registration-directed trial in recurrent or metastatic
patients with HRAS mutant HNSCC. In addition, tipifarnib is being
evaluated in multiple other Phase 2 clinical trials in solid tumor
and hematologic indications. Kura’s pipeline also includes KO-947,
an ERK inhibitor, currently in a Phase 1 dose-escalation trial, and
KO-539, a menin-MLL inhibitor, which has been cleared to begin a
Phase 1 clinical trial.
Forward-Looking Statements
Statements contained in this press release
regarding matters that are not historical facts are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Such
forward-looking statements include, without limitation, statements
about Kura’s expectations regarding the completion and timing of
the proposed offering, and its expectations with respect to
granting the underwriters a 30-day option to purchase additional
shares. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Words such
as “believes,” “anticipates,” “plans,” “expects,” “intends,”
“will,” “goal,” “potential” and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are based upon Kura’s current expectations and involve
assumptions that may never materialize or may prove to be
incorrect. Actual results and the timing of events could
differ materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties, which
include, without limitation, risks associated with market
conditions and the satisfaction of closing conditions related to
the proposed public offering, as well as risks and uncertainties
associated with Kura’s business and finances in general, and the
other risks described in Kura’s quarterly report on Form 10-Q for
the quarterly period ended March 31, 2019 and other
filings with the SEC. All forward-looking statements contained in
this press release speak only as of the date on which they were
made. Kura undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
Contacts
Company:Pete De SpainVice President, Investor Relations
&Corporate Communications(858)
500-8803pete@kuraoncology.com
Investors:Robert H. UhlManaging DirectorWestwicke Partners,
LLC(858) 356-5932robert.uhl@westwicke.com
Media:Jason SparkManaging DirectorCanale Communications(619)
849-6005jason@canalecomm.com
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Mar 2023 to Mar 2024